Connection
David Camidge to Receptor, IGF Type 1
This is a "connection" page, showing publications David Camidge has written about Receptor, IGF Type 1.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.417 |
|
|
|
-
Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):419-26.
Score: 0.417